Christian Nitsche

MD, PhD, Medical University of Vienna, University College London, Cardiac Imaging Fellow @KardiologieWien @BartsHospital

[Journal of Cardiac Failure @JCardFail]

#ESC2025 Check out this new meta-analysis that harmonizes data from all phase-3 trials assessing disease-specific Rx in ATTR-CM. There were early improvements in biomarkers, QoL & functional capacity, followed by⬇️CV events & ACM with continued treatment.🔗https://t.co/ogATHvUPqm

[Christian Nitsche @MdNitsche]

Dual Approach the Best Remedy for Aortic Stenosis, Amyloidosis: Registry https://t.co/mOjXD3PR3c

[EHJ Editor-in-Chief @ehj_ed]

Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis. Read more in the @EHJ at https://t.co/1gjnpL73h2 #AorticValveReplacement #AmyloidosisAwareness @ESCardio @ESC_Journals

[Christian Nitsche @MdNitsche]

🚨Excited to see the results of our transatlantic registry published in #EHJ.
In dual aortic stenosis and ATTR-CM: treat the valve AND the myocardium. AVR and ATTR-specific medication ↓ mortality.
https://t.co/gfQaCplGIu
#CardioTwitter
@ESC_Journals

[Thomas Treibel @ThomasTreibel]

3/3_🧠 Implication:
Dual pathology (AS + ATTR-CA) should not preclude intervention.
Combined AVR and disease-modifying therapy may restore prognosis.
Non-randomised, but compelling signal for integrated treatment. @EurHeartJ
#TAVR #Amyloidosis
@JoaoCavalcante @Marco_Merlo

[Thomas Treibel @ThomasTreibel]

2/3_👥 N=226 (mean age 85)
🔹 71% had AVR (mostly TAVI)
🔹 32% received tafamidis
🔍 Results:
Both AVR and tafamidis independently ↓ mortality
Dual therapy (AVR + tafamidis) = best outcomes
Survival similar to patients with lone AS undergoing AVR
#EHJ #ValveDisease @MdNitsche

[JACC Journals @JACCJournals]

#JACCINT is proud to honor Dr. Christian Nitsche w/ the Spencer King Award for Outstanding Scholarship for his groundbreaking research on managing fluid overload in pts w/ severe AS (EASE-TAVR)! 🎉

📎: https://t.co/gG96KxAQ4C

#ACC25 #TheFaceOfCardiology #TAVR #vhdAS @MdNitsche

[Christian Nitsche @MdNitsche]

EASE-TAVR RCT: Targeted Management of Fluid Overload in Patients With Severe Aortic Stenosis Undergoing TAVR
✅️ improves clinical outcomes
✅️ improves quality of life

#Cardiology #Valve
@JACCJournals @a_kammerlander @pe_bartko @heitzin

[Christian Nitsche @MdNitsche]

Expansion of the NAC staging system to detect early mortality in ATTR-CM🫀
Important for:
🔬clinical trial inclusion criteria
💊potential intensified treatment
@dr_a_ioannou @dr_m_fontana
https://t.co/YipxzSmUFB

[Adam Ioannou @dr_a_ioannou]

Presented at #ACC2024 and #SimPub in @JACCJournals

NT-proBNP progression and ODI detect disease progression and are associated with an increased risk of mortality in cardiac ATTR amyloidosis

https://t.co/E5nKKKmfd6

[JAHA @JAHA_AHA]

Multiorgan blood biomarker abnormalities are common and associated with mortality in ATTR-CA. #AHAJournals @dr_a_ioannou https://t.co/cwfVXmh8VW

[Christian Nitsche @MdNitsche]

@DrAndrewLin @MedUni_Wien @KardiologieWien @CardiacimagingB @LancetDigitalH Many thanks, Andrew!

[Christian Nitsche @MdNitsche]

Delighted to share our work on AI-based detection of cardiac amyloidosis on bone scintigraphy scans. ✅Removes interrater variability
✅Works across all amyloid tracers
✅Predicts outcome
@MedUni_Wien @KardiologieWien @CardiacimagingB @LancetDigitalH https://t.co/hiKyc4wuHq

[The Lancet Digital Health @LancetDigitalH]

NEW Research: Diagnosis and prognosis of abnormal cardiac scintigraphy uptake suggestive of cardiac #amyloidosis using #ArtificialIntelligence: a retrospective, international, multicentre, cross-tracer development and validation study.

Read it here: https://t.co/jDOv13zbdC

[MedUni Wien @MedUni_Wien]

#Cardiacamyloidosis is a serious disease in which abnormal proteins accumulate in the #heart muscle and affect heart function. A team led by #MedUniVienna has now developed an #AI system that can automatically detect cardiac amyloidosis. ➡ https://t.co/Pees09rVra

@TheLancet

[Christian Nitsche @MdNitsche]

Bioprosthetic valve dysfunction after #TAVI occurs at the same rate across the spectrum of life expectancy and is associated w/ higher mortality in patients w/ short but to not in those w/ the longest life expectancy #AorticStenosis #EHJCVI #Echofirst
https://t.co/byVhPTqenC

[Edgardo Alania @Ed_Alania]

🔴How prevalent is cardiac amyloidosis and which patients should be screened? @MdNitsche @ESC_Journals #CardioEd #Cardiology #amyloidosis

[JACC Journals @JACCJournals]

In this short video, Dr. Carolina Donà talks about unveiling cardiac #amyloidosis, its characteristics and outcomes among patients w/ mitral regurgitation undergoing #TEER.

📃 #ESCCongress #JACCINT simpub paper: https://t.co/kVM1mWWjP8

#CardioTwitter #ACCIntl #vhdMR

[Christian Nitsche @MdNitsche]

Dual pathology cardiac amyloidosis and mitral regurgitation is frequent and carries worse outcomes following mitral valve repair
@amyloidosis @mitral @g_heitzinger @pe_bartko @a_kammerlander @m_koschutnik @JMascherbauer @KardiologieWien

AddThis | Home https://t.co/2rilLSsJMy

[Christian Nitsche @MdNitsche]

Reverse Remodeling Following Valve Replacement in Coexisting Aortic Stenosis and Transthyretin Cardiac Amyloidosis | Circulation: Cardiovascular Imaging https://t.co/tYiWTEm7qo